Search
Motexafin gadolinium
go.drugbank.com/drugs/DB05428InvestigationalMotexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. … It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells.
Terlipressin
go.drugbank.com/drugs/DB02638ApprovedInvestigational[A252672] The drug was first approved by the FDA in September 2022.[L43217]
Porfimer sodium
go.drugbank.com/drugs/DB00707ApprovedInvestigationalThe purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentall...
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnWith a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long. … Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis.
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory
Beclomethasone dipropionate
go.drugbank.com/drugs/DB00394ApprovedInvestigationalBeclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray.
Mixtures: FORMODUAL N. 200/6UG, FORMODUAL N. 200/6UGCefpiramide
go.drugbank.com/drugs/DB00430ApprovedCefpiramide is a third-generation cephalosporin antibiotic.
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigationalClobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the liter...
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)